High-capacity poly (2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma
Open accessPublished version of a preprint
The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Polymeric micelle formulation of an immune modulator improves survival in a highly aggressive model of non–small cell lung cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Frequently employed combinations are 1) a combination of several chemotherapies for killing cancer cells, 2) a combination of chemotherapy with additional agents, such as tumor microenvironment modifiers, or more recently 3) a combination of immunotherapy with anticancer agents [259].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [259]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The latest study highlighted that even the best combinations of the chemotherapeutic agents determined in vitro as having the most potent and highly synergistic effect against non-small cell lung cancer (NSCLC) cells may not be effective against the in vivo tumor even at the MTD of those combinations [259].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [259]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In contrast, resiquimod, an imidazoquinoline TLR 7/8 agonist, solubilized in POx block copolymer (PMeOx-b-PBuOx-b-PMeOx) micelles had a superior tumor inhibitory effect in a metastatic model of lung adenocarcinoma, relative to anti-PD1 immune checkpoint blockade therapy as well as platinum-based chemotherapy, which is the mainstay of treatment for NSCLC.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [259]
The cited source says what the claim attributes to it.
In the citing paper
“Investigation of the in vivo immune status following resiquimod in polymeric micelles treatment showed that resiquimod-based stimulation of antigen-presenting cells in the tumor microenvironment resulted in the mobilization of anti-tumor CD8+ immune response [259].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [259]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“Certain cancers overexpress PD-L1 to benefit from PD-1/PD-L1 axis–mediated suppression of adaptive immunity (3).”
Drug combination studies and their synergy quantification using the Chou-Talalay method
Chou, T.-C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1947 · Cited by 5,739 · cited 1×
“4 of 12 of Chou and Talalay, which states that a CI value of less than 1 represents synergy, whereas a CI value greater than 1 indicates antagonism (24).”
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212 · cited 1×
“IL-6 signaling is again pivotal to the differentiation of T and B cells (30).”
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760 · cited 1×
“However, the initial response to cisplatin is often short-lived because of the development of drug resistance (17).”
Non-small-cell lung cancers: a heterogeneous set of diseases
Chen, Z., Fillmore, C. M., Hammerman, P. S., Kim, C. F., & Wong, K.-K. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3775 · Cited by 1,942 · cited 2×
“Nevertheless, the benefits of such interventions are often transient due to the development of chemoresistance, which primarily stems from tumor-host cell interactions (1).”
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G., & Schoenberger, S. P. (2003) · Nature · doi:10.1038/nature01441 · Cited by 1,635
Norelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0036-4 · Cited by 1,406 · cited 1×
“(55) showed both IL-1 and IL-6 (implicated as a key driver of cytokine storm) were involved in the pathogenesis of cytokine storm in a humanized mouse model of leukemia, and because IL-1 signaling preceded IL-6, the blockade of IL-1 receptor was shown to successfully overcome the toxicities associated with the syndrom…”
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau-Guilemond, J., Valsesia-Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,108
Yang, J., Zhang, L., Yu, C., Yang, X.-F., & Wang, H. (2014) · Biomarker Research · doi:10.1186/2050-7771-2-1 · Cited by 1,099 · cited 1×
“Ly6C+ monocytes are prone to differentiate into inflammatory macrophages and secrete TH1 cytokines that activate adaptive immune response (38).”
Rodell, C. B., Arlauckas, S. P., Cuccarese, M. F., Garris, C. S., Li, R., Ahmed, M. S., Kohler, R. H., Pittet, M. J., & Weissleder, R. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0236-8 · Cited by 1,099
Chen, L., Gibbons, D. L., Goswami, S., Cortez, M. A., Ahn, Y.-H., Byers, L. A., Zhang, X., Yi, X., Dwyer, D., Lin, W., et al. (2014) · Nature Communications · doi:10.1038/ncomms6241 · Cited by 966
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Pfirschke, C., Engblom, C., Rickelt, S., Cortez-Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., et al. (2016) · Immunity · doi:10.1016/j.immuni.2015.11.024 · Cited by 952
Chresta, C. M., Davies, B. R., Hickson, I., Harding, T., Cosulich, S., Critchlow, S. E., Vincent, J. P., Ellston, R., Jones, D., Sini, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1751 · Cited by 812 · cited 1×
“mTOR is a serine/threonine kinase involved in the regulation of cell growth and autophagy (21).”
Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-14-3362 · Cited by 785 · cited 1×
“However, only a minority of PD-L1–positive patients with NSCLC respond to anti–PD-1 therapy due, in part, to intratumoral and temporal heterogeneity of pathologically regulated PD-L1 expression, underscoring the role of the pathophysiological state of the tumor microenvironment in dictating treatment response to anti–…”
MyD88: a central player in innate immune signaling
Deguine, J., & Barton, G. M. (2014) · F1000Prime Reports · doi:10.12703/p6-97 · Cited by 692
Choi, C.-H. (2005) · Cancer Cell International · doi:10.1186/1475-2867-5-30 · Cited by 523
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade
Chen, L., Diao, L., Yang, Y., Yi, X., Rodriguez, B. L., Li, Y., Villalobos, P. A., Cascone, T., Liu, X., Tan, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1033 · Cited by 462
Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines
Liebmann, J., Cook, J., Lipschultz, C., Teague, D., Fisher, J., & Mitchell, J. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.488 · Cited by 428
Zabludoff, S. D., Deng, C., Grondine, M. R., Sheehy, A. M., Ashwell, S., Caleb, B. L., Green, S., Haye, H. R., Horn, C. L., Janetka, J. W., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0492 · Cited by 413
Tumour angiogenesis regulation by the miR-200 family
Pecot, C. V., Rupaimoole, R., Yang, D., Akbani, R., Ivan, C., Lu, C., Wu, S., Han, H.-D., Shah, M. Y., Rodriguez-Aguayo, C., et al. (2013) · Nature Communications · doi:10.1038/ncomms3427 · Cited by 402
Self-citationOsteoblasts remotely supply lung tumors with cancer-promoting SiglecF high neutrophils
Engblom, C., Pfirschke, C., Zilionis, R., Da Silva Martins, J., Bos, S. A., Courties, G., Rickelt, S., Severe, N., Baryawno, N., Faget, J., et al. (2017) · Science · doi:10.1126/science.aal5081 · Cited by 389 · cited 1×
“Signaling interactions between cancer cells and neighboring immune cells lead to the protumorigenic evolution of the latter, yielding cells that lack antitumor properties (7).”
TIR domain-containing adaptors define the specificity of TLR signaling
Yamamoto, M., Takeda, K., & Akira, S. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2003.10.006 · Cited by 343 · cited 1×
“MyD88 is an important adaptor protein that mediates the association between TLRs and IL-1R–associated kinases (IRAKs) and thereby triggers the activation of mitogen-activated protein kinases (MAPKs) and IB kinase (IKK) complex, ultimately leading to the nuclear translocation and transcription of nuclear factor B (NF…”
Doubly amphiphilic poly(2-oxazoline)s as high-capacity delivery systems for hydrophobic drugs
Luxenhofer, R., Schulz, A., Roques, C., Li, S., Bronich, T. K., Batrakova, E. V., Jordan, R., & Kabanov, A. V. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.02.057 · Cited by 286
Self-citationAbid, A. D., Anderson, D. S., Das, G. K., Van Winkle, L. S., & Kennedy, I. M. (2013) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-10-1 · Cited by 270
Tumor-Selective Induction of Apoptosis and the Small-Molecule Immune Response Modifier Imiquimod
Schon, M., Bong, A. B., Drewniok, C., Herz, J., Geilen, C. C., Reifenberger, J., Benninghoff, B., Slade, H. B., Gollnick, H., & Schon, M. P. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg016 · Cited by 258
Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery
Dou, H., Destache, C. J., Morehead, J. R., Mosley, R. L., Boska, M. D., Kingsley, J., Gorantla, S., Poluektova, L., Nelson, J. A., Chaubal, M., et al. (2006) · Blood · doi:10.1182/blood-2006-03-012534 · Cited by 253
Rossi, A., & Di Maio, M. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1170596 · Cited by 245
Cavalcanti, M. G., Cunha, A. F. A., & Peralta, J. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00858 · Cited by 223
The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy
Smits, E. L. J. M., Ponsaerts, P., Berneman, Z. N., & Van Tendeloo, V. F. I. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0097 · Cited by 215 · cited 6×
“Resiquimod PM Resiquimod is an imidazoquinoline immune response modifier that stimulates TLR 7 in mice and TLR 7/8 in humans (12).”
InfluentialThe pharmacokinetics of Toll-like receptor agonists and the impact on the immune system
Engel, A. L., Holt, G. E., & Lu, H. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.5 · Cited by 205 · cited 3×
“Toll-like receptor (TLR) agonists are a class of immune-stimulating agents that have shown promising immune-enhancing effects in both human and animal models of cancers (11).”
InfluentialWan, X., Beaudoin, J. J., Vinod, N., Min, Y., Makita, N., Bludau, H., Jordan, R., Wang, A., Sokolsky, M., & Kabanov, A. V. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.032 · Cited by 201 · cited 2×
“It should be noted that the superadditive therapeutic effect of drug combinations is strongly influenced by the drug ratios (15).”
Self-citationHe, Z., Wan, X., Schulz, A., Bludau, H., Dobrovolskaia, M. A., Stern, S. T., Montgomery, S. A., Yuan, H., Li, Z., Alakhova, D., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.06.002 · Cited by 197 · cited 4×
“The drug loading capacity and loading efficiency of the POx micelles were calculated as described previously (14).”
Self-citationAdaptation and memory in immune responses
Natoli, G., & Ostuni, R. (2019) · Nature Immunology · doi:10.1038/s41590-019-0399-9 · Cited by 179 · cited 1×
“Although the investigation of the antitumor memory response was beyond the scope of this study, it is well recognized that activation and deployment of the adaptive immune surveillance generate long-term immunological memory that can counter cancer recurrence (56).”
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade
Shergold, A. L., Millar, R., & Nibbs, R. J. B. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104258 · Cited by 174 · cited 12×
“While this may explain the innate resistance to anti–PD-1 therapy, acquired resistance to anti–PD-1 is a consequence of evolutionary pressure on cancer cells, resulting in PD-L1–independent mechanisms of immune evasion (36, 37).”
InfluentialImmunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities
Morrissey, K., Yuraszeck, T., Li, C., Zhang, Y., & Kasichayanula, S. (2016) · Clinical and Translational Science · doi:10.1111/cts.12391 · Cited by 171
Macropinocytosis of Nab-paclitaxel Drives Macrophage Activation in Pancreatic Cancer
Cullis, J., Siolas, D., Avanzi, A., Barui, S., Maitra, A., & Bar-Sagi, D. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0125 · Cited by 162
Monoclonal antibody-induced cytokine-release syndrome
Bugelski, P. J., Achuthanandam, R., Capocasale, R. J., Treacy, G., & Bouman-Thio, E. (2009) · Expert Review of Clinical Immunology · doi:10.1586/eci.09.31 · Cited by 161
Wan, X., Min, Y., Bludau, H., Keith, A., Sheiko, S. S., Jordan, R., Wang, A. Z., Sokolsky-Papkov, M., & Kabanov, A. V. (2018) · ACS Nano · doi:10.1021/acsnano.7b07878 · Cited by 158 · cited 2×
“The lack of any anticancer activity of POx alone has been previously demonstrated in this model (35).”
Self-citationTargeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment
Cheng, H., Shcherba, M., Pendurti, G., Liang, Y., Piperdi, B., & Perez-Soler, R. (2014) · Lung Cancer Management · doi:10.2217/lmt.13.72 · Cited by 156
Dovedi, S. J., Melis, M. H. M., Wilkinson, R. W., Adlard, A. L., Stratford, I. J., Honeychurch, J., & Illidge, T. (2012) · Blood · doi:10.1182/blood-2012-05-432393 · Cited by 154
Tumor-associated macrophages in cancers
Hu, W., Li, X., Zhang, C., Yang, Y., Jiang, J., & Wu, C. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1373-0 · Cited by 149 · cited 1×
“5 of 12 Characterization of Resiquimod-mediated BMDM activation in vitro Macrophages account for a major percentage of tumor-infiltrating leukocytes (26).”
Wagstaff, A. J., & Perry, C. M. (2007) · Drugs · doi:10.2165/00003495-200767150-00006 · Cited by 115 · cited 1×
“2 of 12 basal cell carcinoma, precancerous actinic keratoses, and genital and perianal warts (12, 13).”
Morgan, H., & Hill, P. A. (2005) · Cancer Cell International · doi:10.1186/1475-2867-5-1 · Cited by 112
Singh‐Jasuja, H., Thiolat, A., Ribon, M., Boissier, M., Bessis, N., Rammensee, H., & Decker, P. (2012) · Immunobiology · doi:10.1016/j.imbio.2012.01.021 · Cited by 109 · cited 1×
“This observation was consistent with the finding by Decker and co-workers (39) that the CD11c marker is down-regulated upon activation of mouse dendritic cells by TLR stimulation.”
IL-1 Strikingly Enhances Antigen-Driven CD4 and CD8 T-Cell ResponsesPreprint
Ben-Sasson, S. Z., Wang, K., Cohen, J. I., & Paul, W. E. (2013) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2013.78.021246 · Cited by 106 · cited 1×
“IL-1 is an important TH1 cytokine that promotes anticancer immune response by activating and expanding CD4 and CD8 T effector cells (29).”
Doxsee, C. L., Riter, T. R., Reiter, M. J., Gibson, S. J., Vasilakos, J. P., & Kedl, R. M. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1156 · Cited by 102
Therapeutic Silencing of KRAS Using Systemically Delivered siRNAs
Pecot, C. V., Wu, S. Y., Bellister, S. A., Filant, J., Rupaimoole, R., Hisamatsu, T., Bhattacharya, R., Maharaj, A., Azam, S. H., Rodriguez‐Aguayo, C., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0074 · Cited by 96
Self-citationRegulation of the IL-10-driven macrophage phenotype under incoherent stimuli
Chuang, Y., Hung, M. E., Cangelose, B. K., & Leonard, J. N. (2016) · Innate Immunity · doi:10.1177/1753425916668243 · Cited by 94 · cited 2×
“This could be due to the 4-hour time frame as the expression of TNF- is reportedly low at early time points following macrophage stimulation (27).”
Therapeutic Implication of SOCS1 Modulation in the Treatment of Autoimmunity and Cancer
Sharma, J., & Larkin, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00324 · Cited by 81 · cited 1×
“8 of 12 Downmodulation of systemic cytokine signaling is a widely accepted mechanism of immune system regulation involving the SOCS (suppressor of cytokine signaling) family of proteins to keep immune disorders caused by constitutive expression of proinflammatory proteins in check (43).”
Sauder, D. N., Smith, M. H., Senta-McMillian, T., Soria, I., & Meng, T. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.12.3846-3852.2003 · Cited by 74
What, Why, Where, and When: Bringing Timing to Immuno-Oncology
Rothschilds, A. M., & Wittrup, K. D. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.11.003 · Cited by 72 · cited 1×
“From the recognition of tumor antigen to the infiltration of antitumor T cells, the development of immune response follows a coordinated sequence of events lasting several days (50).”
Zhao, B., Wang, X., Wang, X.-Y., Zhang, H., Dai, W., Wang, J., Zhong, Z., Wu, H., & Zhang, Q. (2013) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-10-47 · Cited by 65 · cited 1×
“However, following treatment of mice with these micelles, inflammatory mediators were not detected in the plasma of these animals (31).”
Schölch, S., Rauber, C., Tietz, A., Rahbari, N. N., Bork, U., Schmidt, T., Kahlert, C., Haberkorn, U., Tomai, M. A., Lipson, K. E., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3081 · Cited by 64 · cited 1×
“Despite a promising therapeutic profile, toxicity resulting from hyperstimulation of the immune system (also known as cytokine storm) is a major bottleneck to clinical translation of TLR agonists (51).”
Renaud, S., Seitlinger, J., Falcoz, P.-E., Schaeffer, M., Voegeli, A.-C., Legrain, M., Beau-Faller, M., & Massard, G. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.182 · Cited by 64 · cited 1×
“Postsurgical recurrence and metastasis is a principal cause of mortality in a substantial percentage of NSCLC cases (2).”
Cheng, L., Zhang, Z., Li, G., Li, F., Wang, L., Zhang, L., Zurawski, S., Zurawski, G., Lévy, Y., & Su, L. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.09.052 · Cited by 55 · cited 1×
“Owing to the fundamental differences in the innate immunity between mice and humans, mice do not exhibit clinical signs of cytokine storm and, therefore, may have a poor predictive value for the human disease (52, 53).”
Liposomal resiquimod for the treatment of Leishmania donovani infection
Peine, K. J., Gupta, G., Brackman, D. J., Papenfuss, T. L., Ainslie, K. M., Satoskar, A. R., & Bachelder, E. M. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt320 · Cited by 47
Predictive factors of response to immunotherapy—a review from the Spanish Melanoma Group (GEM)
On behalf of the Spanish Melanoma Group (GEM), Espinosa, E., Márquez‐Rodas, I., Soria, A., Berrocal, A., Manzano, J. L., González‐Cao, M., & Martín‐Algarra, S. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.08.10 · Cited by 36 · cited 1×
“Insufficient numbers of tumor-infiltrating T cells preclude response to immunotherapeutic strategies such as anti–PD-1 therapy that primarily act on preexisting anticancer T cells (45).”
Vascotto, F., Petschenka, J., Walzer, K. C., Vormehr, M., Brkic, M., Strobl, S., Rösemann, R., Diken, M., Kreiter, S., Türeci, Ö., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1601480 · Cited by 25 · cited 1×
“This was not unexpected as previous studies have shown that proinflammatory cytokines return to baseline levels approximately 24 hours after TLR agonist dosing in normal mice (41, 42).”
Zsíros, E., & Odunsi, K. O. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.10.012 · Cited by 16 · cited 1×
“In addition, TAMs can dampen the adaptive immune response by impeding the tumor infiltration of CD8+ cytotoxic T cells (9).”
Bird, L. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0030-6 · Cited by 15 · cited 1×
“Nonetheless, research on the management of the cytokine storm has demonstrated that it can be managed by blocking specific cytokines without compromising efficacy (54).”
Liang, X., Yang, Q., Wang, W., Liu, T., & Hu, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s211560 · Cited by 13 · cited 1×
“Three different chemosensitizers were evaluated for coformulation with the alkylated prodrug of cisplatin (C6CP): (i) AZD7762—a chemosensitizer that can inhibit the DNA repair activity by checkpoint kinases following treatment with DNA-damaging agents such as cisplatin and, thus, improve the therapeutic margin of chem…”
PD-L1 copy number gains: a predictive biomarker for PD-1/PD-L1 blockade therapy?
Inoue, Y., Osman, M., Suda, T., & Sugimura, H. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.07.47 · Cited by 4
PD-L1 copy number gains: a predictive biomarker for PD-1/PD-L1 blockade therapy?
Inoue, Y., Osman, M., Suda, T., & Sugimura, H. (2016) · Translational Cancer Research · doi:10.21037/8810 · Cited by 2 · cited 1×
“However, only a minority of PD-L1–positive patients with NSCLC respond to anti–PD-1 therapy due, in part, to intratumoral and temporal heterogeneity of pathologically regulated PD-L1 expression, underscoring the role of the pathophysiological state of the tumor microenvironment in dictating treatment response to anti–…”
Cited by
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
Self-citationDecoding Toll-like receptors: Recent insights and perspectives in innate immunity
Kawai, T., Ikegawa, M., Ori, D., & Akira, S. (2024) · Immunity · doi:10.1016/j.immuni.2024.03.004 · Cited by 528
Bhagchandani, S., Johnson, J. A., & Irvine, D. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.013 · Cited by 188
Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives
Sun, H., Li, Y., Zhang, P., Xing, H., Zhao, S. Q., Song, Y., Wan, D., & Yu, J. (2022) · Biomarker Research · doi:10.1186/s40364-022-00436-7 · Cited by 166
“Another study showed that R848-based stimulation of APCs in the tumor microenvironment resulted in the mobilization of an antitumor CD8+ immune response for treating metastatic NSCLC [70].”
BackgroundInfluentialZahoranová, A., & Luxenhofer, R. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202001382 · Cited by 119
Metadata
- Authors
- Vinod, N., Hwang, D., Azam, S. H., Van Swearingen, A. E. D., Wayne, E., Fussell, S. C., Sokolsky-Papkov, M., Pecot, C. V., & Kabanov, A. V.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
- Center for Nanotechnology in Drug Delivery and Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, USA.
- Corresponding author
- Pecot, Chad V.
- Kabanov, Alexander V.
- ORCID
- Venue
- Science Advances
- Published
- 2020-06-17
- Volume
- 6
- Issue
- 25
- Pages
- eaba5542-eaba5542
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC7299629
- OpenAlex
- W3036026766
- Cited by
- 63
- References
- 64
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 5 · 2023: 8 · 2022: 20 · 2021: 18 · 2020: 2
- FWCI
- 4.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion, cc-by-nc)
- UNC Libraries
- Funders
- National Institutes of Health (5U54CA198999-05)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Keywords
- poly(2-oxazoline), resiquimod, TLR7/8 agonist, lung adenocarcinoma, metastatic non-small cell lung cancer, drug formulation, survival, cancer immunotherapy
- MeSH terms
- Adenocarcinoma of Lung, Adjuvants, Immunologic, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Oxazoles, Toll-Like Receptor 7, Toll-Like Receptor 8, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.